Target intelligence / Profile preview

Choline-binding protein D (CbpD)

Target
CbpD
Molecular classification
Other (surface-associated protein/modular protein), Choline-binding protein family, Bacterial cell wall-binding protein, Adhesin
01

Overview

Choline-binding protein D is a modular surface protein found in *Streptococcus pneumoniae* and related bacteria. It binds to choline molecules present on bacterial cell wall teichoic acids through a series of conserved choline-binding repeats (CBRs), organizing into an elongated, superhelical structure. This anchoring allows CbpD to mediate bacterial cell wall remodeling, cell separation, adherence to host tissues, and enhances bacterial virulence during infection. CbpD is thought to play an important role in pneumococcal pathogenesis, making it a potential target for antibacterial drug discovery or novel therapeutic interventions aimed at disrupting pathogenic mechanisms. CbpD consists of distinct domains: an N-terminal signal peptide, a central region often involved in particular interactions, and a C-terminal choline-binding domain assembled from several choline-binding repeats. It is non-enzymatic but can function in concert with autolysins or other enzymes that participate in cell wall turnover. Its loss or mutation can attenuate bacterial virulence and impact colonization, underlining its value as a drug target.

Other names
CBP-DCbpD
02

Mechanism of action

Block choline-binding interactions, preventing anchoring to cell wall. Inhibit the protein's contribution to cell separation and virulence.

03

Biological functions

Cell wall binding (interaction with choline residues of teichoic acids)Cell division and separation (facilitates remodeling of cell wall)Virulence factor (contributes to pathogenesis, immune system evasion)Adhesion to host cellsPotential autolysin regulation (related CBPs can regulate autolytic enzymes)
04

Disease associations

Infection (especially bacterial pneumonia caused by Streptococcus pneumoniae)Other (implicated in bacterial pathogenesis and immune modulation)
05

Safety considerations

No direct safety concerns associated with the molecule as a therapeutic target itself, but general antibacterial therapy targeting CBPs may cause bacterial cell lysis, release of inflammatory components, or disruption of normal flora.

Beyond the preview

Go deeper on Choline-binding protein D (CbpD).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Choline-binding protein D (CbpD).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call